Role of centchroman versus danazol in treatment of benign breast disorders

Autor:	Saurabh Sharma, Devendra Saini, Hanuman Ram Khoja, Bodu Ram Barala, Prabha Om
Rok vydání:	2021
Předmět:	Drug Danazol medicine.medical_specialty business.industry media_common.quotation_subject Breast pain Breast Disorder Bromocriptine Internal medicine Medicine medicine.symptom skin and connective tissue diseases business Prospective cohort study Tamoxifen Menstrual cycle media_common medicine.drug
Zdroj:	International Surgery Journal. 8:616
ISSN:	2349-2902 2349-3305
DOI:	10.18203/2349-2902.isj20210372
Popis:	Background: The breast is a dynamic structure that undergoes cyclical changes throughout the menstrual cycle. Any aberration from normal physiological changes in breast produces different problem in breast. Many drugs are used for treatment for these disorders like Danazol, Bromocriptine, Tamoxifen and LH-RH analogue but still no consensus for any drug is present.Methods: The aim of our study was to analyze the effectiveness of drug Centchroman and its comparison with Danazol in treatment of benign breast disorders in respect to symptoms relief, decrease in nodularity and lump size, recurrence, cost and side effects of drug. This prospective study was conducted on 250 patients of benign breast disorders attending surgical OPD between May 2018 to September 2019 in SMS medical college and Hospital, Jaipur.Results: Tolerance and improvements in symptoms in centchroman group was more than danazol (100% vs 92.8%) with less recurrence in former group. While side effects varied between the two groups with menstrual irregularities more common in centchroman group.Conclusions: The study shows that centchroman is safe, more effective and less expensive to Danazol for the treatment of benign breast disorders in long term.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::df766653982daddf0fd16ed32eacce5a https://doi.org/10.18203/2349-2902.isj20210372 Zobrazit plný text záznamu